Abstract

Model systems for microbicide evaluations are inadequate. In vitro tests can provide support for drug efficacy but cannot reproduce the complex vaginal environment. The vaginas of experimental animals are poorly characterized and do not provide a sufficient representation of the human counterpart. In this project, we will modify our human xenograft system so that grafts of human vagina can be used for microbicide evaluation.
The Specific Aims of the study are as follows: 1. Define the Composition of human Vaginal Xenografts 2. Determine Human Vaginal Xenografts Responsiveness to Sex Steroids 3. Test the Susceptibility of Human Vaginal Xenografts to Primary infections with Selected Pathogens 4. Determine the Effectiveness and Toxicity of Selected Microbicides on Pathogens in Human Vaginal Xenografts.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI037829-04
Application #
6099889
Study Section
Project Start
1998-09-01
Project End
1999-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost

  Institution

Name
Pennsylvania State University
Department
Type
DUNS #
129348186
City
Hershey
State
PA
Country
United States
Zip Code
17033

  Publications

Passic, Shendra R; Ferguson, Mary Lee; Catalone, Bradley J et al. (2010) Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1. Biomed Pharmacother 64:723-32
Pavlovic, Jelena; Floros, Joanna; Phelps, David S et al. (2008) Differentiation of xenografted human fetal lung parenchyma. Early Hum Dev 84:181-93
Deka, Srilekha; Vanover, Jennifer; Dessus-Babus, Sophie et al. (2006) Chlamydia trachomatis enters a viable but non-cultivable (persistent) state within herpes simplex virus type 2 (HSV-2) co-infected host cells. Cell Microbiol 8:149-62
Hartmann, Sandra Urdaneta; Berlin, Cheston M; Howett, Mary K (2006) Alternative modified infant-feeding practices to prevent postnatal transmission of human immunodeficiency virus type 1 through breast milk: past, present, and future. J Hum Lact 22:75-88; quiz 89-93
Fang, L; Budgeon, L R; Doorbar, J et al. (2006) The human papillomavirus type 11 E1/E4 protein is not essential for viral genome amplification. Virology 351:271-9
Beer, Brigitte E; Doncel, Gustavo F; Krebs, Fred C et al. (2006) In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother 50:713-23
Fang, L; Meyers, C; Budgeon, L R et al. (2006) Induction of productive human papillomavirus type 11 life cycle in epithelial cells grown in organotypic raft cultures. Virology 347:28-35
Hartmann, Sandra Urdaneta; Wigdahl, Brian; Neely, Elizabeth B et al. (2006) Biochemical analysis of human milk treated with sodium dodecyl sulfate, an alkyl sulfate microbicide that inactivates human immunodeficiency virus type 1. J Hum Lact 22:61-74
Urdaneta, Sandra; Wigdahl, Brian; Neely, Elizabeth B et al. (2005) Inactivation of HIV-1 in breast milk by treatment with the alkyl sulfate microbicide sodium dodecyl sulfate (SDS). Retrovirology 2:28
Krebs, Fred C; Miller, Shendra R; Ferguson, Mary Lee et al. (2005) Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1. Biomed Pharmacother 59:438-45

Showing the most recent 10 out of 35 publications